研究名称、年份 及研究类型 | 样本量 | 年龄 | 性别(male) | ECOG PS: 0/1 | Child-Pugh Class: A/B |
Kudo 2018/RCT | Lenvatinib: 478 | 63.0 (20~88) | 405 (85%) | 304 (64%)/ 174 (36%) | 475 (99%)/ 3 (1%) |
Sorafenib: 476 | 63.0 (20~88) | 401 (84%) | 301 (63%)/ 175 (37%) | 471 (99%)/ 5 (1%) | |
Yamashita 2019/ RCT | Lenvatinib: 81 | 63.0 (20~88) | 65 (80%) | 76 (94%)/ 5 (6%) | 81 (100%)/ 0 (0%) |
Sorafenib: 87 | 63.0 (20~88) | 72 (83%) | 75 (86%)/ 12 (14%) | 87 (100%)/ 0 (0%) | |
Briggs 2020/RCT | Lenvatinib: 478 | 63.0 (20~88) | 405 (85%) | 304 (64%)/ 174 (36%) | 475 (99%)/ 3 (1%) |
Sorafenib: 476 | 63.0 (20~88) | 401 (84%) | 301 (63%)/ 175 (37%) | 475 (99%)/ 3 (1%) | |
Kim 2020/ 回顾性对列研究 | Lenvatinib: 44 | 56.0 (51.0~66.3) | 39 (88.6%) | 41 (93.2%)/ 3 (6.8%) | 36 (81.8%)/ 8 (18.2%) |
Sorafenib: 61 | 64.0 (58.0~70.5) | 51 (83.6%) | 59 (96.7%)/ 2 (3.3%) | 56 (91.8)/ 5 (8.2%) | |
KUZUYA 2020/ 回顾性队列研究 | Lenvatinib: 13 | 70 (53~92) | 11 (84.6%) | 12 (92.3%)/ 1 (7.7%) | 5/6:8 (61.5%)/ 5 (38.5%) |
Sorafenib: 13 | 69 (60~78) | 11 (84.6%) | 8 (61.5%)/ 5 (38.5%) | 5/6:7 (53.8%)/ 6 (46.2%) | |
Nakano 2020/ 回顾性队列研究 | Lenvatinib: 146 | 73.9 (44.7~89.8) | 125 (86%) | NR | 134 (92%)/ 12 (8%) |
Sorafenib: 146 | 73.1 (48.3~94.3) | 121 (83%) | NR | 137 (94%)/ 9 (6%) | |
Tomonari 2020/ 回顾性队列研究 | Lenvatinib: 52 | 70 (53~88) | 36 pts | 0/1, n: 38/14 | 5/6, n Lenvatinib: 27/25 |
Sorafenib: 52 | 71 (43~85) | 36 pts | 37/15 | 5/6, n Sorafenib: 27/25 |